Structural and Physical Basis for Anti-IgE Therapy

Abstract

Omalizumab, an anti-IgE antibody, used to treat severe allergic asthma and chronic idiopathic urticaria, binds to IgE in blood or membrane-bound on B lymphocytes but not to IgE bound to its high (Fc? RI) or low (CD23) affinity receptor. Mutagenesis studies indicate overlapping Fc? RI and omalizumab-binding sites in the C? 3 domain, but crystallographic studies show Fc? RI and CD23-binding sites that are far apart, so how can omalizumab block IgE from binding both receptors? We report a 2.42-Å omalizumab-Fab structure, a docked IgE-Fc/omalizumab-Fab structure consistent with available experimental data, and the free energy contributions of IgE residues to binding omalizumab, CD23, and Fc? RI. These results provide a structural and physical basis as to why omalizumab cannot bind receptor-bound IgE and why omalizumab-bound IgE cannot bind to CD23/Fc? RI. They reveal the key IgE residues and their roles in binding omalizumab, CD23, and Fc? RI.